Barriers to Access for COVID-19 Treatments Put Patients With Cancer at Risk - Targeted Oncology

Amid the surge of the omicron variant, the FDA issued an emergency use authorization for the orally administered antiviral combination, which can reduce the rate hospitalization or death by 87% compared with no treatment.

There has been welcome news recently in the field of treatments for COVID-19. Amid the surge of the omicron variant, the FDA issued an emergency use authorization for the orally administered antivira… [+2464 chars]

full article...